기업 프로필 · Healthcare

Laboratory Corporation of America Holdings

LH · 미국
거래소
미국
국가 / 지역
USA
상장일
1990년 3월 29일
직원 수
71,000
웹사이트
www.labcorp.com
현재가
$255.82
실시간 · 2026년 6월 18일
적정 매수가
≤ $210
안전마진 진입가
베일리 성장 점수
44/100
다소 약함
내재가치 · 3단계 구간 현재가 $255.82 실시간 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 $145–$200 / 적정 $220–$280 / 낙관적 $280–$326. $255.82 기준, 적정 내재가치 구간 내.

보고서 발행 시 $262.75(2026년 5월 29일)

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North

시가총액US$213.17억
매출 (TTM)US$141.44억
EBITDAUS$22.53억
순이익률6.66%
ROE11.05%
PER (TTM)23.05
선행 PER14.77
PEG1.12
EPSUS$11.28
배당수익률1.09%
52주 범위US$239.28 – US$291.40
애널리스트 목표주가US$310.12
애널리스트 평가4.5 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.